Biogen, a biotechnology company specializing in therapies for neurodegenerative diseases, and certain of the company’s executives were hit with a securities class action Monday in Massachusetts District Court. The lawsuit, brought by Block & Leviton, accuses the defendants of engaging in back-channel meetings with Billy Dunn, Office of Neuroscience chief for the Food and Drug Administration, in an effort to gain approval for Aduhelm, a drug meant to treat Alzheimer’s disease that had already failed to obtain approval. The complaint asserts that these meetings are now being investigated by the federal government. Counsel have not yet appeared for the defendants. The case is 1:22-cv-10200, Oklahoma Firefighters Pension and Retirement System v. Biogen Inc. et al.

This suit was surfaced by Radar, a source for high-speed legal news and litigation updates personalized to your practice. Radar publishes daily updates on just-filed federal cases like this one. Click here to get started and be first to know about new suits in your region, practice area or client sector.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]